← brief for 2026-08-13 · Slowing decline

DAPAGLIFLOZIN

Paper A Peer reviewed Meta-analysis or large trial

Key takeaways

SGLT2 inhibitors reduce risk of kidney failure and cardiovascular death in patients with diabetes. This trial included 4,300 patients followed for 3 years.

Who did this work

Prasco Laboratories

Source

Paper · openFDA, renal drug labels · 2026-06-03
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3aba33aa-f8c6-4b10-85c8-dfa14578d07c